AbbVie Inc.
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
4 leaders · 2013 to present
AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.
AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.
Chairman and Chief Executive Officer
2024 – Present
2 years (current)
Michael became CEO in 2024 and now serves as chairman and CEO. He previously served as president, chief operating officer, chief financial officer, and a key architect of AbbVie's business development and diversified growth strategy.
Executive Vice President and Chief Financial Officer
2023 – Present
3 years (current)
Reents leads AbbVie's finance organization through debt management, capital allocation, dividend policy, investor communication, and the financial transition after Humira's U.S. loss of exclusivity.
Executive Vice President, Research and Development and Chief Scientific Officer
2021 – Present
5 years (current)
Thakkar leads AbbVie's R&D organization across immunology, oncology, neuroscience, aesthetics, and pipeline programs connected to both internal research and external innovation.
Founding Chairman and CEO
2013 – 2024
11 years
Gonzalez led AbbVie from its 2013 spin-off through Humira's peak, the Pharmacyclics acquisition, the Allergan acquisition, and the beginning of the Skyrizi/Rinvoq replacement strategy. He retired from the CEO role in 2024.
AbbVie must manage biosimilar pressure on Humira, future patent cliffs, drug-pricing scrutiny, payer access constraints, pipeline risk, and intense competition from larger pharmaceutical and biotech companies.
Robert A. Michael is AbbVie's current chairman and chief executive officer.
Robert A. Michael became AbbVie's CEO on July 1, 2024.
Richard A. Gonzalez was AbbVie's founding CEO from the 2013 spin-off until the 2024 CEO transition.
Michael is known for finance, commercial operations, business development, and leading the company through the post-Humira growth phase.
Important AbbVie executives include CFO Scott Reents and R&D leader Roopal Thakkar.